Not Yet RecruitingPhase 3ACTRN12611000794909

The effect of intravenous sedation on the lower oesophageal sphincter: A comparison between dexmedetomidine and remifentanil in healthy adult volunteers.


Sponsor

Dr Islam Elhalawani

Enrollment

16 participants

Start Date

Sep 1, 2011

Study Type

Interventional

Conditions

Summary

The primary aim of this study is to assess the effect of sedation on lower oesophageal sphincter (LOS) function and to compare the effects of two types of sedating drugs, Remifentanil and Dexmedetomidine, on LOS function. This is performed to assess the risk of aspiration during sedation both in theatres as well as the intensive care unit.


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 55 Yearss

Plain Language Summary

Simplified for easier understanding

This study compares the effects of two sedation drugs — dexmedetomidine and remifentanil — on the valve between the oesophagus and stomach in healthy volunteers aged 18-55. The goal is to understand which sedation option is less likely to cause stomach acid reflux during procedures.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Sedation of Healthy volunteers. Cross over study between 2 sedation medications: Remifentanil and Dexmedetomidine. Remifentanil Sedation: Target-Controlled Infusion: 0.1, 0.2, 0.3 and 0.4 mcg/Kg/min.

Sedation of Healthy volunteers. Cross over study between 2 sedation medications: Remifentanil and Dexmedetomidine. Remifentanil Sedation: Target-Controlled Infusion: 0.1, 0.2, 0.3 and 0.4 mcg/Kg/min. Duration: 20 minutes at each target concentration. Period between cross-over: 1 week Target controlled infusions will be administered consecutively in an ascending pattern (lower to higher concentrations)


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611000794909